Table 1.
Treatment | N | Body weight (g) | Kidney weight (g) | Kidney weight/ body weight (×103) | E2 (pg/ml) | Uterine weight (mg wet weight) |
---|---|---|---|---|---|---|
Sham | 5 | 24.7 ± 0.1 | 0.13 ± 0.01 | 4.3 ± 0.2 | 12.32 ± 4.0 | 0.25 ± 0.03† |
Placebo | 6 | 25.88 ± 1.9 | 0.13 ± 0.03 | 5.2 ± 0.8 | 5.35 ± 1.6 | 0.09 ± 0.02 |
CE2 | 6 | 24.3 ± 2.2 | 0.16 ± 0.02* | 6.5 ± 0.5* | 20.39 ± 6.8* | 0.15 ± 0.05* |
IE2 | 5 | 24.8 ± 2.6 | 0.14 ± 0.02 | 5.6 ± 0.8 | 29.82 ± 7.9† | 0.17 ± 0.02* |
Tam | 5 | 24.32 ± 1.3 | 0.11 ± 0.01 | 4.5 ± 0.3 | ND | 0.04 ± 0.02 |
CE2, continuous 17β-estradiol treatment; IE2, intermittent 17β-estradiol treatment; Tam, tamoxifen; ND, not done.
P < 0.05,
P < 0.005 compared to placebo.